secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057461
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics appoints George Scangos to Board of Directors
------------------------------------------------------------------

- George Scangos, Ph.D., appointed as Class I director effective May 9, 2023, serving until 2025 annual meeting.
- Scangos will serve on the Science and Technology Committee of the Board.
- Compensation includes $40,000 annual cash retainer and initial option for 44,000 shares vesting over 4 years.
- Scangos brings experience as former CEO of Biogen, Vir Biotechnology, and Exelixis.
- He will enter standard indemnification agreement with Voyager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923057461/0001104659-23-057461-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923057461/tm2314979d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057461

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer